Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H29N4O12P4.Sm |
Molecular Weight | 698.1954 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[153Sm+3].OP(O)(=O)CN1CCN(CP(O)([O-])=O)CCN(CP(O)([O-])=O)CCN(CP(O)([O-])=O)CC1
InChI
InChIKey=LNBUCNBAQQFTBL-GJNDDOAHSA-K
InChI=1S/C12H32N4O12P4.Sm/c17-29(18,19)9-13-1-2-14(10-30(20,21)22)5-6-16(12-32(26,27)28)8-7-15(4-3-13)11-31(23,24)25;/h1-12H2,(H2,17,18,19)(H2,20,21,22)(H2,23,24,25)(H2,26,27,28);/q;+3/p-3/i;1+3
Molecular Formula | Sm |
Molecular Weight | 152.9221 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C12H29N4O12P4 |
Molecular Weight | 545.2733 |
Charge | -3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
SAMARIUM SM-153 is a β- and γ-emitter with a physical half-life around 46.8 hours. Sm-153 treatment is recommended for patients with multiple bone metastases with the osteoblastic component, regardless of the primary tumor’s location. This compound was used in prostate cancer. It was shown that the small influence of Sm-153 on hematological parameters in patients treated with Sm-153, because of the high affinity of Sm-153 to osteoblastic metastases, and of the effect of low concentration of radionuclide in healthy bone tissue.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28373820
118 patients received single doses of placebo or Sm-153 of dose 0.5 mCi/kg or 1.0 mCi/kg
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 14:39:35 GMT 2023
by
admin
on
Sat Dec 16 14:39:35 GMT 2023
|
Record UNII |
S5NN2E9ZKF
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
773120
Created by
admin on Sat Dec 16 14:39:35 GMT 2023 , Edited by admin on Sat Dec 16 14:39:35 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
633308-21-1
Created by
admin on Sat Dec 16 14:39:35 GMT 2023 , Edited by admin on Sat Dec 16 14:39:35 GMT 2023
|
PRIMARY | |||
|
C165558
Created by
admin on Sat Dec 16 14:39:35 GMT 2023 , Edited by admin on Sat Dec 16 14:39:35 GMT 2023
|
PRIMARY | |||
|
S5NN2E9ZKF
Created by
admin on Sat Dec 16 14:39:35 GMT 2023 , Edited by admin on Sat Dec 16 14:39:35 GMT 2023
|
PRIMARY | |||
|
54671408
Created by
admin on Sat Dec 16 14:39:35 GMT 2023 , Edited by admin on Sat Dec 16 14:39:35 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |